Cannabix Technologies Develops Beta 3.0 Marijuana Breathalyzer and Provides Update

7934 Government Road, Burnaby, B.C., V5A 2E2

Phone: (604) 551-7831 Fax: 604-676-2767

info@cannabixtechnologies.com

cannabixtechnologies.com

The Cannabix Marijuana Breathalyzer is being developed to give law enforcement and employers a tool to enforce public safety

Vancouver, BC -- July 31, 2017 -- InvestorsHub NewsWire -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (the “Company or Cannabix”) developer of the Cannabix Marijuana Breathalyzer for law enforcement and the workplace, is pleased to announce that it has developed a “Beta 3.0” (Cannabix Marijuana Breathalyzer) device based on its FAIMS- (field asymmetric waveform ion mobility spectrometry) technology with major advances in the design and commercial capabilities of the device. The Beta 3.0 will include a conventional rechargeable battery, improved ion flow, the latest pulse driver chips to improve resolution and sensitivity. The new design includes improvements that will allow for dynamic testing and for easier configurability that will be needed for more demanding test/user environments.

The Beta 3.0 device will also include a specialized flow-through heat exchanger technology that stabilizes breath temperature in cold as well as humid temperature settings and allows for breath testing in all temperature conditions. The new device includes improved dielectric barrier discharge ionization source and high-voltage square wave generator which has been given superior voltage shielding. The Beta 3.0 device incorporates real time breath analysis for concentrations of O₂, CO₂, humidity, temperature and flow-rate which will allow for key metrics for real-time detection of delta-9-tetrahydrocannabinol (“THC”) in human breath.

Testing update and Establishment of British Columbia Testing Laboratory

Cannabix has been developing its FAIMS based Cannabix Marijuana Breathalyzer for the detection of THC through exhaled breath and continues testing its devices in British Columbia and Florida for sensitivity and consistency of results for Evidential Breath testing purposes.

Recent testing with the Cannabix Marijuana Breathalyzer Beta 2.0 prototype device with human subjects after smoking THC cigarettes demonstrated the successful identification of THC in relation to the subject’s background matrix in real-time. (THC being the psychoactive component of marijuana). In addition to THC, several metabolites were identified in the breath of the human subjects including 11-hydroxy-delta-9-tetrahydrocannabinol and delta-9-carboxy-tetrahydrocannabinol, the results were confirmed by mass spectrometry after the inhalation of cannabis.

The Company has substantially increased its testing capabilities with investment in a state-of-the art lab space in Vancouver, B.C., purchase of Thermo Scientific mass spectrometer and related equipment. Cannabix has also added to its technical team with the addition of Dr. David Hasman who is an expert in the field of toxicology and forensic science as well the operation of mass spectrometer based testing devices.

Furthermore, the Company is in discussions to collaborate, using the Cannabix Marijuana Breathalyzer, with a significant U.S. based institution with large user group and enhanced testing environment.

About Cannabix Technologies Inc

Cannabix Technologies Inc. is a leader in marijuana breathalyzer development for law enforcement and the workplace. Cannabix has established breath testing technologies in the pursuit of bringing durable, portable hand-held tools to market to enhance detection of marijuana impaired driving offences on roads at a time when marijuana is becoming legal in many global jurisdictions. Cannabix is working to develop drug-testing devices that will detect THC- the psychoactive component of marijuana that causes intoxication- using breath samples. In particular, Cannabix is focused on developing breath testing devices for detection of recent use of THC, in contrast to urine testing for THC metabolite that requires an invasive collection and reflects use days or even weeks earlier. The devices will also be useful for other practical applications such as testing employees in the workplace where intoxication by THC can be hazardous.
We seek Safe Harbor.
On behalf of the Board of Directors

“Rav Mlait”

CEO
Cannabix Technologies Inc.

For further information, contact the Company at info@cannabixtechnologies.com

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking information that involves various risks and uncertainties regarding future events. Such forward-looking information can include without limitation statements based on current expectations involving a number of risks and uncertainties and are not guarantees of future performance of the Company, such as final development of a commercial or prototype product(s), successful trial or pilot of company technologies, no assurance that commercial sales of any kind actually materialize; no assurance the Company will have sufficient funds to complete product development. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information, including: (i) adverse market conditions; (ii) risks regarding protection of proprietary technology; (iii) the ability of the Company to complete financings; (v) the ability of the Company to develop and market its future product; and (vi) risks regarding government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition and other factors which may be identified from time to time in the Company's public announcements and filings. There is no assurance that the marijuana breathalyzer business will provide any benefit to the Company, and no assurance that any proposed new products will be built or proceed. There is no assurance that existing “patent pending” technologies licensed by the Company will receive patent status by regulatory authorities. The Company is not currently selling commercial breathalyzers. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.